Prof. Mengxian Zhang 张孟贤
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of head and neck tumors, brain tumors, lung cancer, esophageal cancer, gastrointestinal tumors, breast cancer, lymphoma, and urogenital tumors using radiotherapy, chemotherapy, and molecular targeted therapy.
Dr. Zhang holds a medical doctorate and completed postdoctoral research at the German Cancer Research Center/Heidelberg University. With nearly 20 years in oncology, Dr. Zhang specializes in precise radiotherapy using image-guided 3D conformal and intensity-modulated techniques. Dr. Zhang has led or participated in multiple national and provincial research projects and published over 30 academic papers.
Professional roles
- Standing Committee Member, Tumor Radiotherapy Professional Committee, Hubei Anti-Cancer Association
- Member, Radiotherapy Group, Glioma Professional Committee, Chinese Medical Doctor Association
- Member, International Academic Cooperation and Exchange Group, Glioma Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Mengxian). Papers usually list the name as Mengxian Zhang or Zhang M.
Selected publications
28 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Decoding the spatiotemporal dynamics of T cell immune landscapes in glioblastoma: remodeling precision combination therapies. PubMed 42628660
- BMC Cancer, 2026 (senior author): Decoding lactylation heterogeneity in glioblastoma: machine learning identifies G6PC3 as a prognostic target. PubMed 42192326
- Int J Gen Med, 2026 (senior author): Dual Regulation of Post-Translational Modification of Proteins: Bottlenecks and Breakthroughs in NK Cell Therapy for Glioblastoma. PubMed 41873355
- Int J Mol Sci, 2025 (senior author): Lactylation in Glioblastoma: A Novel Epigenetic Modifier Bridging Epigenetic Plasticity and Metabolic Reprogramming. PubMed 40244246
- Biomedicines, 2025 (senior author): Constructing a Glioblastoma Prognostic Model Related to Fatty Acid Metabolism Using Machine Learning and Identifying F13A1 as a Potential Target. PubMed 40002669
- BMC Med Genomics, 2024 (senior author): Integrated bioinformatics analysis and experimental validation reveal the relationship between ALOX5AP and the prognosis and immune microenvironment in glioma. PubMed 39169376
- J Cell Mol Med, 2022 (senior author): Annexin-1 is an oncogene in glioblastoma and causes tumour immune escape through the indirect upregulation of interleukin-8. PubMed 35770335
- Oncol Rep, 2020 (senior author): ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion. PubMed 32323832
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion